Alanna Church, MD (she/her/hers)
Associate Director, Laboratory for Molecular Pediatric Pathology (LaMPP)
Boston Children's Hospital
Boston, Massachusetts, United States
Description: This session will review recently published expert consensus recommendations for clinical molecular laboratories for the detection of homologous recombination deficiency (HRD) in cancer, developed by the AMP Clinical Practice Committee’s PARP HRD Working Group. With representation from the Association of Cancer Care Centers, American Society of Clinical Oncology, and College of American Pathologists, the Working Group developed these recommendations, informed by the findings from a scoping literature review, laboratory practice survey, stakeholder input, and the cumulative practice experience of the members. The recommendations encompass pre-analytical, analytical, and postanalytical factors that play a role in genomic instability and/or HRD analytical validation and reporting.
Learning Objectives:
- Identify challenges in detecting and reporting homologous recombination deficiency.
- Discuss recommendations for clinical HRD assay validation, testing, and reporting.
If this session topic is of interest to you, please consider looking at the following course on AMP EDucation (AMPED™ Online)
Title: Testing for Homologous Recombination Deficiency in Cancer: Diagnostic Strategies and Clinical Perspectives
Please Click Here to Learn More.
Breakout Speaker: Susan J. Hsiao, MD, PhD – Columbia University
Breakout Panelist: Lawrence Jennings, MD, PhD – Northwestern University
Breakout Panelist: Anna Yemelyanova, MD – Weill Cornell Medical College